Korsana Posts $46.4M Q3 Loss, $456.2M Cash Funds Operations Into 2029
KRSA has more than doubled off its 52-week low of $7.186.
Summary
Korsana closed the September merger with Cyclerion Therapeutics and a concurrent $380 million private placement, leaving it with about $456.2 million in cash as of September 30, 2026 — enough to fund operations into 2029. Third-quarter net loss was $46.4 million, or $3.19 a share, including $15.2 million of non-cash stock-based compensation, on R&D of $42.1 million and G&A of $6.1 million. The balance sheet is the story here: the company now has runway well past the first clinical readouts for its lead Alzheimer's asset KRSA-028. Phase 1 healthy volunteer data is expected mid-2027, with interim proof-of-concept data in Alzheimer's patients by year-end 2027 or the first quarter of 2028. Near-term, a preclinical poster (P338) on KRSA-028 characterization is set for presentation at CTAD on November 18, 2026. The company also added a Chief Medical Officer, a Chief Technical Officer and an audit committee chair. This follows the 8-K filed today with the same quarterly figures.
At the time of this announcement, KRSA was trading at $30.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.19 to $59.36. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.